Transposon Therapeutics, Inc.

Return to TPN-101


Expanded Access Policy

Expanded Access Policy
Transposon Therapeutics Inc. does not currently accept or grant requests for expanded access to TPN-101 outside of clinical trials. To learn more about our ongoing TPN-101 clinical programs, please see the PSP, ALS, FTD and AGS sections of our webpage or consult

This Expanded Access Policy applies generally to all investigational drugs manufactured or distributed by Transposon for use in serious diseases or conditions.

21st Century Cures Act
The 21st Century Cures Act asks investigational drug manufacturers like Transposon to publicly post our policy on evaluating and responding to requests submitted for expanded access under section 561(b) of the US Federal Food, Drug, and Cosmetic Act.

At such time as Transposon begins to make expanded access to any of our investigational drugs available, this website and policy will be updated to notify the public of the procedures for making expanded access requests and our criteria for evaluating such requests.

Additional questions may be directed to Transposon at Transposon typically responds to inquiries about our Expanded Access Policy within 5 working days.